亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy

医学 电子健康 随机对照试验 物理疗法 临床终点 不利影响 临床试验 人口 癌症 病人教育 内科学 生活质量(医疗保健) 医疗保健 家庭医学 护理部 经济 环境卫生 经济增长
作者
Kate L. Absolom,Lorraine Warrington,Eleanor Mae Hudson,Jenny Hewison,Carolyn Morris,Patricia Holch,Robert Carter,Andrea Gibson,Marie Holmes,Beverly Clayton,Zoe Rogers,Lucy McParland,Mark T. Conner,Liz Glidewell,Barbara Woroncow,Bryony Dawkins,Sarah Dickinson,Claire T. Hulme,Julia M. Brown,Galina Velikova
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (7): 734-747 被引量:338
标识
DOI:10.1200/jco.20.02015
摘要

PURPOSE Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID) is an online eHealth system for patients to self-report symptoms during cancer treatment. It provides automated severity-dependent patient advice guiding self-management or medical contact and displays the reports in electronic patient records. This trial evaluated the impact of eRAPID on symptom control, healthcare use, patient self-efficacy, and quality of life (QOL) in a patient population treated predominantly with curative intent. METHODS Patients with colorectal, breast, or gynecological cancers commencing chemotherapy were randomly assigned to usual care (UC) or the addition of eRAPID (weekly online symptom reporting for 18 weeks). Primary outcome was symptom control (Functional Assessment of Cancer Therapy-General, Physical Well-Being subscale [FACT-PWB]) assessed at 6, 12, and 18 weeks. Secondary outcomes were processes of care (admissions or chemotherapy delivery), patient self-efficacy, and global quality of life (Functional Assessment of Cancer Therapy–General, EQ5D-VAS, and EORTC QLQ-C30 summary score). Multivariable mixed-effects repeated-measures models were used for analyses. Trial registration: ISRCTN88520246. RESULTS Participants were 508 consenting patients (73.6% of 690 eligible) and 55 health professionals. eRAPID compared to UC showed improved physical well-being at 6 ( P = .028) and 12 ( P = .039) weeks and no difference at 18 weeks (primary end point) ( P = .69). Fewer eRAPID patients (47%) had clinically meaningful physical well-being deterioration than UC (56%) at 12 weeks. Subgroup analysis found benefit in the nonmetastatic group at 6 weeks ( P = .0426), but not in metastatic disease. There were no differences for admissions or chemotherapy delivery. At 18 weeks, patients using eRAPID reported better self-efficacy ( P = .007) and better health on EQ5D-VAS ( P = .009). Average patient compliance with weekly symptom reporting was 64.7%. Patient adherence was associated with clinician's data use and improved FACT-PWB at 12 weeks. CONCLUSION Real-time monitoring with electronic patient-reported outcomes improved physical well-being (6 and 12 weeks) and self-efficacy (18 weeks) in a patient population predominantly treated with curative intent, without increasing hospital workload.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kk完成签到 ,获得积分10
1秒前
2秒前
CAOHOU的应助被初景采纳,获得10
6秒前
8秒前
Honos完成签到,获得积分10
8秒前
心灵美正豪完成签到,获得积分10
10秒前
11秒前
浅荫发布了新的文献求助10
14秒前
霸气远锋完成签到,获得积分10
19秒前
19秒前
涂豆泥发布了新的文献求助30
24秒前
25秒前
2589发布了新的文献求助10
31秒前
老孟完成签到,获得积分10
32秒前
35秒前
大方大船完成签到,获得积分10
40秒前
43秒前
48秒前
Maestro_S的应助被科研通管家采纳,获得10
49秒前
49秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
49秒前
51秒前
缓慢芷文完成签到,获得积分10
52秒前
GXY完成签到,获得积分10
52秒前
msezhj完成签到 ,获得积分10
55秒前
111完成签到,获得积分10
56秒前
56秒前
IGNIS完成签到 ,获得积分10
56秒前
龙龙发布了新的文献求助10
58秒前
59秒前
FashionBoy的应助被2589采纳,获得20
1分钟前
龙龙完成签到,获得积分10
1分钟前
平淡的友儿完成签到 ,获得积分10
1分钟前
浮云发布了新的文献求助20
1分钟前
坦率寻菡完成签到,获得积分10
1分钟前
1分钟前
直率的宛丝完成签到,获得积分10
1分钟前
1分钟前
1分钟前
待续完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565479
关于积分的说明 21780029
捐赠科研通 7764837
什么是DOI,文献DOI怎么找? 3431499
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476579